Cited by 332Schizophrenia research and treatmentTreatment of Major DepressionMental Health and Psychiatry

The DOI matches its Crossref record; 116 of the 118 references it cites were found in a registry or an index.

Guidelines for the Pharmacotherapy of Schizophrenia in Adults

Open access

Remington, Gary, Addington, Donald, Honer, William, Ismail, Zahinoor, Raedler, Thomas, Teehan, Michael·2017·The Canadian Journal of Psychiatry

DOI 10.1177/0706743717720448PMC PMC5593252

Open this paper in CoChat — free account Open PDF

Abstract

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Method: Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline. Results: Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines. Conclusions: In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.

Integrity signals

Registry

Crossref · 10.1177/0706743717720448

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
The Scottish Intercollegiate Guidelines Network (SIGN)
Miller, J. (2002) · The British Journal of Diabetes · doi:10.1177/14746514020020010401 · Cited by 1,546
Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.
Perkins, D., Gu, H., Boteva, K., & Lieberman, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,304
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,187
Self-citation
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis.
Penttilä, M., Jääskeläinen, E., Hirvonen, N., Isohanni, M., & Miettunen, J. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.127753 · Cited by 716

Show all 118 references

Research works printed but not linked: 12

National Collaborating Centre for Mental Health, 2013, National Clinical Guideline Number, 155
Agid O, 2006, J Psychiatry Neurosci, 31, 93
Kane JM, 1996, J Clin Psychiatry, 57, 35
Asenjo Lobos C, 2010, Cochrane Database Syst Rev, CD006633
Rhoades HM, 1988, Psychopharmacol Bull, 24, 101
Woerner MG, 1988, Psychopharmacol Bull, 24, 112
Powney MJ, 2012, Cochrane Database Syst Rev, 11, CD009377
Gillies D, 2013, Cochrane Database Syst Rev, 4, CD003079
Volavka J, 2013, Psychiatr Danub, 25, 24
Kane JM, 2003, J Clin Psychiatry, 64, 5
Whitehead C, 2002, Cochrane Database Syst Rev, CD002305
Cipriani A, 2011, BMJ Clin Evid, 1

Sorted by citations

Items 101–200 of 332

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
Kane, J. M., & Rubio, J. M. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231157219 · Cited by 12
Role of accredited social health activists in treatment of persons with severe mental illness in the community
Sivakumar, T., Kumar, C. N., & Thirthalli, J. (2022) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_702_21 · Cited by 12
Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review
Asian Network of Early Psychosis Writing Group, Hui, C. L. M., Chen, E. Y. H., Verma, S., Tagata, H., Mizuno, M., Liu, C., Takeuchi, H., Kim, S., & Chung, Y. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac002 · Cited by 11
Investigating Cannabidiol's potential as a supplementary treatment for schizophrenia: A narrative review
Völker, J. S. D., Micluția, I., & Vinași, R.-C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176821 · Cited by 14
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design
Li, X., Guo, X., Fan, X., Feng, T., Wang, C., Yao, Z., Xu, X., Chen, Z., Wang, H., Xie, S., et al. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.010 · Cited by 13
Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics
Kaikoushi, K., Karanikola, M. N. K., Middleton, N., Bella, E., & Chatzittofis, A. (2021) · BJPsych Open · doi:10.1192/bjo.2021.982 · Cited by 12
Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
Kim, J., Pae, C., Han, C., Bahk, W., Lee, S.-J., Patkar, A. A., & Masand, P. S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.4.600 · Cited by 11
Clozapine prescription rates in Southeast Europe: A cross-sectional study
Russo, M., Ristić, D. I., Cohen, D., Arënliu, A., Bajraktarov, S., Kulenović, A. D., Stevović, L. I., Marić, N. P., Novotni, A., & Jovanović, N. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123246 · Cited by 13
Recent advances in the development of asenapine formulations
Suresh, A., Narayan, R., & Nayak, U. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1792439 · Cited by 11
Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs
Bramante, S., Salvo, G. D., Maina, G., & Rosso, G. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s374696 · Cited by 9
Risperidone ISM ® : review and update of its usefulness in all phases of schizophrenia
Messer, T., Bernardo, M., Anta, L., & Martínez, J. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241280046 · Cited by 10
Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients
Meyer, J. M., Simmons, A., Jiang, Y., Graham, C. E., Yagoda, S., & McDonnell, D. (2022) · CNS Spectrums · doi:10.1017/s1092852922000967 · Cited by 10
Infections associated with clozapine: a pharmacovigilance study using VigiBase®
Chrétien, B., Brazo, P., Silva, A. D., Sassier, M., Dolladille, C., Lelong‐Boulouard, V., Alexandre, J., & Fédrizzi, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1260915 · Cited by 10
Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients
Birur, B., Kraguljac, N. V., VerHoef, L., Morgan, C. J., Jindal, R. D., Reid, M. A., Luker, A. T., & Lahti, A. C. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0700-6 · Cited by 11
Prevalence of severe cardiovascular disease in patients with schizophrenia
Marche, J.-C., Bannay, A., Baillot, S., Masson, V. D., Leveque, P., Schmitt, C., Laprévote, V., Schwan, R., & Dobre, D. (2021) · L Encéphale · doi:10.1016/j.encep.2021.02.008 · Cited by 10
Predictors of clozapine discontinuation at 2 years in treatment-resistant schizophrenia
Iruretagoyena, B., Castañeda, C. P., Mena, C., Díaz, C., Nachar, R., Ramírez-Mahaluf, J. P., González‐Valderrama, A., Undurraga, J. P., MacCabe, J. H., & Crossley, N. A. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.07.024 · Cited by 12
Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: a cohort study, 2008-2017
Fulone, I., Silva, M. T., & Lopes, L. C. (2023) · Epidemiologia e Serviços de Saúde · doi:10.1590/s2237-96222023000300015 · Cited by 10
DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs
CASALE, A. D., Simmaco, M., Modesti, M. N., Zocchi, C., Arena, J. F., Bilotta, I., Alcibiade, A., Sarli, G., Cutillo, L., Antonelli, G., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11072088 · Cited by 9
Gut microbiota of patients insusceptible to olanzapine-induced fatty liver disease relieves hepatic steatosis in rats
Wu, Q., Wang, J., Tu, C., Chen, P., Deng, Y., Yu, L., Xu, X., Fang, X., & Li, W. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00167.2024 · Cited by 9
Need adapted use of medication in the open dialogue approach for psychosis: a descriptive longitudinal cohort study
Bergström, T., Seikkula, J., Köngäs‐Saviaro, P., Taskila, J. J., & Aaltonen, J. (2022) · Psychosis · doi:10.1080/17522439.2022.2134444 · Cited by 9
Differential Effects of Clozapine and Haloperidol on the 40 Hz Auditory Steady State Response-mediated Phase Resetting in the Prefrontal Cortex of the Female Sprague Dawley Rat
Raza, M. U., Gautam, D., Rorie, D., & Sivarao, D. V. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac203 · Cited by 9
The effects of antipsychotic discontinuation or maintenance on the process of recovery in remitted first-episode psychosis patients – A systematic review and meta-analysis of randomized controlled trials
Béchard, L., Desmeules, C., Bachand, L., Huot‐Lavoie, M., Corbeil, O., Anderson, E. L., Brodeur, S., LeBlanc, A., Demers, M., Lauzier, S., et al. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.5 · Cited by 9
Clozapine Use in 22q11.2 Deletion Syndrome
Colijn, M. A. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001816 · Cited by 9
Real-World Treatment of Schizophrenia in Adults With a 22q11.2 Microdeletion: Traitement dans le monde réel de la schizophrénie chez des adultes atteints du syndrome de microdélétion 22q11.2
Van, L., Heung, T., Reyes, N. G. D., Boot, E., Chow, E. W. C., Corral, M. R., & Bassett, A. S. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241293983 · Cited by 10
Correlation Between Clozapine and CRP Levels in Relation to Smoking Status
Smith, R. L., Andreassen, O. A., Kane, J. M., Schoretsanitis, G., & Molden, E. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13801 · Cited by 9
Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia
Gamón, V., Hurtado, I., Salazar-Fraile, J., & Sanfélix‐Gimeno, G. (2021) · Scientific Reports · doi:10.1038/s41598-021-92731-w · Cited by 9
Neutrophil Myeloperoxidase-Mediated N-Demethylation of Quetiapine Leads to N-Desalkylquetiapine, a Pharmacologically Active Cytochrome P450 Metabolite
Rashid, M. H., Babu, D., Tran, N. H., Reiz, B., & Siraki, A. G. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00008 · Cited by 9
Management of schizophrenia in women during the perinatal period: a synthesis of international recommendations
Lefebvre, A., Pouchon, A., Bioulac, S., Mallet, J., Polosan, M., & Dondé, C. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2102421 · Cited by 10
Clinical efficacy and neurobiological correlates of electroconvulsive therapy in patients with clozapine-resistant/intolerant schizophrenia: study protocol of multi-site parallel arm double-blind randomized sham-controlled study
Arumugham, S. S., Praharaj, S. K., Shreekantiah, U., Sreeraj, V. S., Roy, C., Shenoy, S., Purohith, A. N., Uppinkudru, C., Bagali, K. B., Venkataramaiah, S., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.18028.2 · Cited by 9
Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance
Wei, Y., Wang, X., Yang, X., Wang, C., Wang, L., Xu, X., Zhao, G., Li, B., Zhu, D., Wu, Q., et al. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i11.937 · Cited by 9
Real-world effectiveness of antipsychotic treatments in 1011 acutely hospitalized patients with schizophrenia: A one-year follow-up study
Hatta, K., Katayama, S., Ishizuka, T., Sudo, Y., Nakamura, M., Hasegawa, H., Imai, A., Morikawa, F., Shimada, T., Misawa, F., et al. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102917 · Cited by 8
The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment
Schoretsanitis, G., Correll, C. U., Agorastos, A., Compaired, A., Erzın, G., Grigoras, R. M., Benussi, M. G., Gondek, T. M., Gülöksüz, S., Højlund, M., et al. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2367138 · Cited by 8
Strategies for Achieving Better Cognitive Health in Individuals with Schizophrenia Spectrum: A Focus on the Canadian Landscape: Stratégies pour atteindre une meilleure santé cognitive chez les personnes souffrant du spectre de la schizophrénie : un regard sur le paysage canadien
Lepage, M., Guimond, S., Raedler, T. J., McNeely, H. E., Ungar, T., Margolese, H. C., & Best, M. W. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241261928 · Cited by 8
Self-citation
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation
Lagreula, J., de Timary, P., Elens, L., & Dalleur, O. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221112587 · Cited by 8
Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in Singapore
Yang, Z., Takeuchi, H., Yee, J. Y., See, Y. M., Tang, C. Y. Z., Ng, B. T., & Lee, J. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.10.001 · Cited by 8
Antipsychotic prescribing practices and their association with rehospitalization in a forensic psychiatric sample
Goody, J., Petersen, K. L., Brink, J., Crocker, A. G., & Nicholls, T. L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1474626 · Cited by 7
Evaluating the Role of Clozapine in Treatment-Resistant Schizophrenia: A Narrative Synthesis of Clinical, Economic, and Quality-of-Life Outcomes
Erlianti, K., Alfaqeeh, M., Puspitasari, I. M., Purba, F. D., & Suwantika, A. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s566527 · Cited by 7
Exposure to psychotropic drugs and breast cancer risk in patients with bipolar disorder and major depressive disorder: a nested case–control study
Li, D., Tsai, S., Chen, T., Liang, C., & Chen, M. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01798-9 · Cited by 7
A review of a recently published guidelines' “strong recommendation” for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine
Noel, C. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.07.287 · Cited by 7
Care Pathways, Health Service Use Patterns and Opportunities for Justice Involvement Prevention Among Forensic Mental Health Clients
Leclair, M., Charette, Y., Caulet, M., & Crocker, A. G. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221076723 · Cited by 7
Perspectives on psychotherapy in Southeast Asia: Insights from psychiatrists and trainees (Part I: Attitudes, current practices and training preferences)
Aunjitsakul, W., Anantapong, K., Werachattawan, N., Jongbovonwiwat, K., Kalayasiri, R., Aniwattanapong, D., Chompoosri, P., Tay, A. T. S., Cheng, S. E. T., Sasidharan, S. N., et al. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104597 · Cited by 6
Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review
Correll, C. U. (2025) · CNS Drugs · doi:10.1007/s40263-025-01206-3 · Cited by 7
Non-antipsychotic medicines and modified electroconvulsive therapy are risk factors for hospital-acquired pneumonia in schizophrenia patients
Yang, Y., Kong, D., Li, Q., Chen, W. J., Zhao, G., Tan, X., Huang, X., Zhang, Z., Feng, C., Xu, M., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1071079 · Cited by 6
Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006–2021
Lin, C., Huang, C., Lin, T.-C., Chan, H., & Chen, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115575 · Cited by 8
Effects of aripiprazole on resting-state functional connectivity of large-scale brain networks in first-episode drug-naïve schizophrenia patients
Feng, S., Zheng, S., Dong, L., Li, Z., Zhu, H., Liu, S., Li, X., Ning, Y., & Jia, H. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.01.020 · Cited by 6
Safety of BEN guidelines in clozapine treatment: A Canadian perspective
Wu, S., Powell, V., Chintoh, A. F., Alarabi, M., Agarwal, S. M., & Remington, G. J. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.01.021 · Cited by 7
Self-citation
Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine
Kitagawa, K., Uekusa, S., Hanai, Y., Kimura, I., Tsukahara, M., Kagawa, A., Sasaoka, K., Sakishiro, Y., Miyake, A., Watanabe, Y., et al. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104047 · Cited by 6
Efficacy and acceptability of interventions to reduce antipsychotic polypharmacy: A systematic review and meta-analysis of randomized clinical trials
Köhler‐Forsberg, O., Højlund, M., Rohde, C., Kemp, A. F., Gregersen, A. T., Mellentin, A. I., & Correll, C. U. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.06.001 · Cited by 6
Start low, go fast? Antipsychotic titration patterns at an inpatient psychiatric hospital
Vadiei, N., Chien, J., Enwereji, J., Myslinski, B., & Guzman, A. (2020) · Mental Health Clinician · doi:10.9740/mhc.2020.09.275 · Cited by 6
Factors Associated With Poor Response to Clozapine in Schizophrenia
Grover, S., Naskar, C., & Chakrabarti, S. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001548 · Cited by 6
Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia
Ward, K. M., & Citrome, L. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2328812 · Cited by 6
Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
Olivares, J. M., González-Pinto, A. M., & Páramo, M. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2021.23 · Cited by 6
Addressing Patients’ Unmet Needs to Improve Outcomes in Schizophrenia
Harvey, P. D., & Kane, J. M. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.ic20018ah3c · Cited by 6
Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
Kim, D. D., Lang, D. J., Warburton, D. E. R., Barr, A. M., White, R. F., Honer, W. G., & Procyshyn, R. M. (2021) · Pharmacy · doi:10.3390/pharmacy9030123 · Cited by 6
Self-citation
Comparison of Efficacy and Safety between Long‐Acting Injectable Antipsychotic Monotherapy and Combination of Long‐Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
Sathienluckana, T., Tiangpattanawong, P., Chaiyasukthananoan, K., Jittayanan, P., Sawetwangsing, H., & Puchsaka, P. (2021) · Schizophrenia Research and Treatment · doi:10.1155/2021/8403986 · Cited by 6
Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness
Cavaliere, V. S., Glassman, M., DiPaula, B. A., Mackowick, M., Wehring, H. J., Liu, F., Chen, S., Park, J., Love, R. C., Richardson, C. M., et al. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.03.006 · Cited by 7
Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study
Wong, K. O., Klarenbach, S. W., Martins, K. J. B., Chue, P. S., Dursun, S. M., Snaterse, M., Guigue, A., So, H., Luu, H., Vu, K. N., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04075-y · Cited by 6
Real-World Prescribing Patterns of Long-Acting Injectable Antipsychotics in Australian Psychiatric Inpatients: Trends, Clinical Outcomes, and Substance Use Prevalence
Akindele, T., & Alwis, K. D. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-025-00511-z · Cited by 5
Pharmacological management of comorbid obsessive–compulsive disorder and chronic non-affective psychosis
Udo, I. I., McDaniel, C., & Chima, C. (2020) · BJPsych Advances · doi:10.1192/bja.2020.57 · Cited by 5
Impact of medications, mood state, and electrode placement on ECT outcomes in treatment-refractory psychosis
Ainsworth, N. J., Avina-Galindo, A. M., White, R. F., Zhan, D., Gregory, E., Honer, W. G., & Vila‐Rodriguez, F. (2022) · Brain stimulation · doi:10.1016/j.brs.2022.08.012 · Cited by 5
Self-citation
Association between olanzapine plasma concentrations and treatment response: A systematic review, meta-analysis and individual participant data meta-analysis
Hadjoudj, J., Konecki, C., Féliu, C., & Djerada, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116236 · Cited by 5
Correlation Between Violence and Antipsychotic Dosage in Schizophrenia: A Secondary Analysis of The Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) Dataset
Tasmim, S., Kolla, N. J., Dada, O. O., Bani‐Fatemi, A., & Luca, V. D. (2019) · Pharmacopsychiatry · doi:10.1055/a-0826-4935 · Cited by 5
A ganglionic blocker and adrenoceptor ligands modify clozapine-induced insulin resistance
Yuen, J. W. Y., Wu, C., Wang, C. K., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105257 · Cited by 4
Self-citation
Associations of Clozapine Use With Psychosocial Functioning and Quality of Life in Patients With Schizophrenia: A Community-Based Cross-Sectional Study
Kim, S., Kim, S., Choe, A. Y., & Kim, E. (2021) · Psychiatry Investigation · doi:10.30773/pi.2021.0190 · Cited by 5
Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
Fontaine, J., Chin, E., Provencher, J.-F., Rainone, A., Wazzan, D., Roy, C. A., Rej, S., Lordkipanidzé, M., & Dagenais‐Beaulé, V. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055454 · Cited by 7
Physical activity as a therapeutic method for non-pharmacological treatment of schizophrenia: A systematic literature review
Cempa, K., Jurys, T., Kluczyński, S., & Andreew-Gamza, M. (2022) · Psychiatria Polska · doi:10.12740/pp/140053 · Cited by 5
Dopamine supersensitivity psychosis and delay of clozapine treatment in patients with treatment-resistant schizophrenia
Masumo, Y., Kanahara, N., Kogure, M., Yamasaki, F., Nakata, Y., & Iyo, M. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000442 · Cited by 5
Association of Antipsychotic Polypharmacy and Two-Year All-Cause Mortality: A Population-Based Cohort Study of 33,221 Italian Continuous Users
Parabiaghi, A., Compagnoni, M. M., D’Avanzo, B., Caggiu, G., Galbussera, A. A., Tettamanti, M., Fortino, I., & Barbato, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072073 · Cited by 7
Clozapine Toxicity Predictor: Deep neural network model predicting clozapine toxicity and its therapeutic dose range
Wysokiński, A., & Dreczka, J. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116256 · Cited by 5
Should we consider microbiota-based interventions as a novel therapeutic strategy for schizophrenia? A systematic review and meta-analysis
Hassib, L., Kanashiro, A., Pedrazzi, J. F. C., Vercesi, B. F., Higa, S., Arruda, Í., Soares, Y., de Souza, A. P., Jordão, A. A., Guimarães, F. S., et al. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100923 · Cited by 6
Investigating DRD2 and HTR2A polymorphisms in treatment-resistant schizophrenia: a comparative analysis with other treatment-resistant mental disorders and the healthy state
CASALE, A. D., Gentile, G., Lardani, S., Modesti, M. N., Arena, J. F., Zocchi, C., Luca, O. D., Parmigiani, G., Angeletti, G., Ferracuti, S., et al. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-01970-9 · Cited by 8
Does the Starting of Clozapine Influence Coprescription of Other Medications?
Grover, S., Naskar, C., & Chakrabarti, S. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001348 · Cited by 5
Tratamiento de la esquizofrenia en México: recomendaciones de un panel de expertos.
Escamilla-Orozco, R. I., Becerra‐Palars, C., Armendáriz-Vázquez, Y., Corlay-Noriega, I. S. Y., Herrera-Estrella, M., Llamas-Núñez, R. E., Luna, Ó. M., Quijada-Gaytán, J.-M., Reyes-Madrigal, F., Rosado-Franco, A., et al. (2021) · Gaceta Médica de México · doi:10.24875/gmm.m21000501 · Cited by 9
Bidirectionality of antiseizure and antipsychotic treatment: A population-based study
Revdal, E., Morken, G., Bakken, I. J., Bråthen, G., Landmark, C. J., & Brodtkorb, E. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108911 · Cited by 5
Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
Fulone, I., Silva, M. T., & Lopes, L. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638001 · Cited by 5
State of the Science: The Hierarchical Taxonomy of Psychopathology (HiTOP)Preprint
Cicero, D. C., Ruggero, C. J., Balling, C. E., Bottera, A. R., Cheli, S., Elkrief, L., Forbush, K. T., Hopwood, C. J., Jonas, K. G., Jutras‐Aswad, D., et al. (2024) · doi:10.31234/osf.io/qjm2t · Cited by 5
Medication beliefs and adherence to antipsychotic medication in patients diagnosed with schizophrenia: The moderating role of doctor–patient communication
Ocansey, G., Teye‐Kwadjo, E., & Osafo, J. (2024) · International Journal of Mental Health · doi:10.1080/00207411.2024.2368286 · Cited by 4
Schizophrenia: advances in pathophysiology, management, and precision medicine
Sawa, A., Chiappelli, J., Hamrah, O., & Cascella, N. G. (2026) · BMJ · doi:10.1136/bmj-2026-635470 · Cited by 4
The association between benzodiazepine prescriptions and the risk of laxative use in schizophrenia treatment
Ochi, S., Tsuboi, T., Hasegawa, N., Hori, H., Ichihashi, K., Imamura, Y., Okada, T., Kodaka, F., Saito, Y., Iga, J., et al. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12499 · Cited by 4
The factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in Taiwan, 2006–2021
Shih, Y.-J., Lin, C., & Chou, L. (2024) · Medicine · doi:10.1097/md.0000000000040897 · Cited by 4
Amisulpride Augmentation of Clozapine in Clozapine-Resistant Schizophrenia: A Case Series
Poonia, S., Sharaf, M., Procyshyn, R. M., White, R., & Rafizadeh, R. (2022) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.3178 · Cited by 4
Clinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs : Une étude de population transversale
Kaster, T. S., Babujee, A., Sharpe, I., Rhee, T. G., Gomes, T., Kurdyak, P. A., Foussias, G., Wijeysundera, D. N., Blumberger, D. M., & Vigod, S. N. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241290181 · Cited by 4
Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study
Ochi, S., Kodaka, F., Hasegawa, N., Tsuboi, T., Ohi, K., Igarashi, S., Fukumoto, K., Iga, J., Muraoka, H., Iida, H., et al. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf011 · Cited by 4
Patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine
Song, J., Borlido, C., Luca, V. D., Burton, L., & Remington, G. J. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.02.050 · Cited by 4
Self-citation
The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
Evernden, C., Giang, I., & Anderson, M. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.09.305 · Cited by 4
Medicinal Plants Used in Management of Various Mental Illnesses in Goma City, Democratic Republic of Congo
Kyolo, S. K., Katuura, E., Bbosa, G. S., Mwebaza, N., Kibendelwa, Z. T., & Nakasujja, N. (2022) · Neuroscience & Medicine · doi:10.4236/nm.2022.131002 · Cited by 4
Trace Amine-Associated Receptor 1 Agonists for Schizophrenia
Vannabouathong, C., Picheca, L., & Dyrda, P. (2022) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2022.392 · Cited by 3
Influence of Psychotropic Pro Re Nata Drug Use on Outcomes in Hospitalized Patients with Schizophrenia
Kyou, Y., Oishi, S., Takizawa, T., Yoshimura, Y., Hashimoto, I., Suzuki, R., Demizu, R., Ono, T., Noguchi, Y., Kimura, T., et al. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2023.21.2.332 · Cited by 4
Clozapine-induced myocarditis in Canada: Evidence from spontaneous reports
Neufeld, N. H., & Remington, G. J. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.11.015 · Cited by 4
Self-citation
Pharmacotherapy management of schizophrenia for family physicians
Bool, J., Crawley, A., Wanson, A., Davis, B., & Halpape, K. (2021) · Canadian Family Physician · doi:10.46747/cfp.6705350 · Cited by 4
Relationship between clozapine dose and severity of obsessive-compulsive symptoms
Kim, D. D., Barr, A. M., Stewart, S. E., White, R. F., Honer, W. G., & Procyshyn, R. M. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110506 · Cited by 4
Self-citation
Polypharmacy in clozapine-treated patients: A retrospective analysis of 667 patients in Ottawa, Canada
Preobrazenski, N., Hsieh, T., Robertson, C. A., Thai, H., & Owoeye, O. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116684 · Cited by 3
A Network Analysis of Psychiatric Symptoms in Patients With Schizophrenia Treated With Antipsychotic Polypharmacy Using Propensity Score Matching: Findings From the Research on Asian Psychotropic Prescription Patterns ( REAP ) Study
Li, W., Zhang, Q., Ungvari, G. S., Park, S., Chen, L., Chee, K. Y., Kallivayalil, R. A., Sim, K., He, Y., Sartorius, N., et al. (2025) · Asia-Pacific Psychiatry · doi:10.1111/appy.70005 · Cited by 3
Personality disorders and schizophrenia spectrum disorders in the Italian forensic psychiatric population: clinical features, pattern of violence and treatment
Margari, A., Catanesi, R., Carabellese, F., Buongiorno, L., Piarulli, F. M., & Mandarelli, G. (2023) · International Review of Psychiatry · doi:10.1080/09540261.2023.2287095 · Cited by 5
Adjunctive methylphenidate extended release in patients with schizophrenia: Protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes
Zhand, N., Attwood, D. G., Labelle, A., Joober, R., Robertson, C., & Harvey, P. D. (2024) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2024.101337 · Cited by 3
Updated rationale for the initial antipsychotic selection for patients with schizophrenia
Markota, M., Morgan, R. J., & Leung, J. G. (2024) · Schizophrenia · doi:10.1038/s41537-024-00492-y · Cited by 3
Antipsychotic prescription patterns among schizophrenia patients in Guangdong Province, China’s 686 program: A retrospective study
Hu, Y., Su, J., Xu, X., Li, J., Zhang, S., & Chen, X. (2024) · Medicine · doi:10.1097/md.0000000000039629 · Cited by 3
Brexpiprazole Oral Soluble Film: A Randomized, Open-Label, Single-Dose, Crossover Bioequivalence Study in Healthy Chinese Volunteers
Wang, T., Shang, L., He, Y., Guo, L., Ruan, X., Han, P., Wu, W., Chen, M., Zhang, F., Hu, C., et al. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.07.001 · Cited by 3
New-generation Antipsychotics and Cardiovascular Risk
Rajagopalan, A. K., Bache, W. K., Chen, S. Z., Bojdani, E., & Li, K. J. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-00173-z · Cited by 3
Maintenance Therapy of Psychosis Spectrum Disorders in a Real-World Setting: Antipsychotics Prescription Patterns and Long-Term Benzodiazepine Use
Marić, N. P., Petrović, S. A., Russo, M., Jerotić, S., Ristić, I., Savić, B., Pemovska, T., Milutinović, M., Ribić, E., Markovska-Simoska, S., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.796719 · Cited by 3

Authors: Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M.
Affiliations: Centre for Addiction and Mental Health (CA)
University of Calgary (CA)
University of British Columbia (CA)
Dalhousie University (CA)
Corresponding author: Remington, Gary
ORCID: Remington, Gary
Addington, Donald
Honer, William
Ismail, Zahinoor
Raedler, Thomas
Venue: The Canadian Journal of Psychiatry
Publisher: SAGE Publications
Published: 2017-07-13
Volume: 62
Issue: 9
Pages: 604-616
ISSN: 0706-7437 (ISSN-L)
1497-0015
DOI: 10.1177/0706743717720448
PMC: PMC5593252
OpenAlex: W2737472140
Cited by: 332
References: 118
Citations by year: 2026: 29 · 2025: 32 · 2024: 46 · 2023: 38 · 2022: 66 · 2021: 56 · 2020: 23 · 2019: 28 · 2018: 13 · 2017: 1
FWCI: 14.59
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: The Canadian Journal of Psychiatry (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Hotchkiss Brain Institute, University of Calgary
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords: schizophrenia, pharmacotherapy, adults, first-episode schizophrenia, acute exacerbation, relapse prevention, maintenance therapy, treatment-resistant schizophrenia, clozapine-resistant schizophrenia, antipsychotic drugs, symptom domains, evidence-based recommendations
MeSH terms: Adult, Canada, Humans, Schizophrenia, Antipsychotic Agents, Practice Guidelines as Topic, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Guidelines for the Pharmacotherapy of Schizophrenia in Adults

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks